Clinical Trials Directory

Trials / Completed

CompletedNCT07023107

NLR and PLR Levels Following PENG Block in Hip Arthroplasty

Pericapsular Nerve Group Block Mitigates Surgical Stress and Enhances Analgesia in Total Hip Arthroplasty: A Randomized Controlled Trial

Status
Completed
Phase
Phase 4
Study type
Interventional
Enrollment
60 (actual)
Sponsor
Poznan University of Medical Sciences · Academic / Other
Sex
All
Age
60 Years – 100 Years
Healthy volunteers
Not accepted

Summary

Effect of PENG block on NLR and PLR following hip arthroplasty

Detailed description

The NLR is a sensitive indicator of inflammation confirmed in numerous studies and has a predictive and prognostic value. NLR is a cheap, simple, fast-acting, readily available stress and inflammation parameter with high sensitivity and low specificity. Dynamic changes in the NLR precede the clinical state by several hours and may alert clinicians to the ongoing pathological process early. NLR is a new promising marker of cellular immune activation, an important indicator of stress and systemic inflammation. It opens a new dimension for clinical medicine, enabling a better understanding of the biology of inflammation, the linkage and antagonism between innate and adaptive immunity, and their clinical consequences for health and disease. NLR is affected not only by surgical trauma but also by the method of anesthesia. In recent years, the influence of regional anesthesiology on reducing the inflammatory response after surgical procedures has been emphasized. However, there have been very few studies evaluating the effect of various methods of anesthesia on the NLR.

Conditions

Interventions

TypeNameDescription
DRUG0.9% Sodium Chloride InjectionAfter spinal anesthesia, the ultrasound-guided PENG block will be performed with 20ml of 0.9% sodium chloride
DRUGRopivacaine 0.2% Injectable SolutionAfter spinal anesthesia, the ultrasound-guided PENG block will be performed with 20 ml of 0.2% ropivacaine

Timeline

Start date
2025-06-16
Primary completion
2025-12-09
Completion
2025-12-09
First posted
2025-06-15
Last updated
2025-12-29

Locations

1 site across 1 country: Poland

Source: ClinicalTrials.gov record NCT07023107. Inclusion in this directory is not an endorsement.